Your browser doesn't support javascript.
loading
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
Koehler, K; Liebner, D; Chen, J L.
Affiliation
  • Koehler K; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus.
  • Liebner D; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus Division of Bioinformatics, Department of Biomedical Informatics, The Ohio State University, Columbus, USA.
  • Chen JL; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus Division of Bioinformatics, Department of Biomedical Informatics, The Ohio State University, Columbus, USA james.chen@osumc.edu.
Ann Oncol ; 27(3): 539-43, 2016 Mar.
Article in En | MEDLINE | ID: mdl-26646755
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Sarcoma / Sulfonamides / Tumor Suppressor Protein p53 / Angiogenesis Inhibitors / Receptors, Vascular Endothelial Growth Factor Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2016 Document type: Article Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Sarcoma / Sulfonamides / Tumor Suppressor Protein p53 / Angiogenesis Inhibitors / Receptors, Vascular Endothelial Growth Factor Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2016 Document type: Article Country of publication: United kingdom